Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Carcinoma × Prednisolone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 27 Lymphoma, Large B-Cell, Diffuse 8 Lymphoma, Follicular 8 Neoplasm Metastasis 5 Ovarian Neoplasms 4 Neoplasms 3 Multiple Myeloma 3 Lymphoma, Non-Hodgkin 3 Lymphoma 3 Metastatic Castration-resistant Prostate Cancer 2 Lymphoma, B-Cell 2 Endometrial Neoplasms 2 Breast Neoplasms 2 Urogenital Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomatitis 1 Stomach Neoplasms 1 Recurrence 1 Prostate Cancer Metastatic 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Peripheral Nervous System Diseases 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Oral Ulcer 1 Myasthenia Gravis 1 Metastatic Castration-Resistant Prostate Cancer Patients 1 Metastatic Castration-Resistant Prostate Cancer 1 Hodgkin Disease 1 Dendritic Cell Sarcoma, Interdigitating 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 30 Cisplatin 23 pembrolizumab 22 Paclitaxel 21 Pemetrexed 20 Gemcitabine 10 osimertinib 9 durvalumab 9 Nivolumab 9 130-nm albumin-bound paclitaxel 8 Sunitinib 7 Sorafenib 7 Fluorouracil 7 Everolimus 7 Docetaxel 7 Cetuximab 6 Axitinib 6 epothilone B 5 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5 volociximab 4 trebananib 4 reolysin 4 catumaxomab 4 cabozantinib 4 atezolizumab 4 Radiotherapy 4 vosaroxin 3 liposomal doxorubicin 3 lenvatinib 3 capmatinib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00822809 2012-10-03

CASIMAS

Neovii Biotech

Phase 3 Completed

Carcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡